Rebirthel Co., Ltd. was founded in October, 2019.
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal
T cells that are regenerated from pluripotent stem cells.
The strategy is based on methods developed by myself, Dr. Hiroshi Kawamoto (Kyoto University).
It has been shown to be effective to transfuse genetically engineered T cells that had originally been collected from patients.
However, such “autologous” settings have faced problems: costly, time-consuming, and dependent on the quality of the T cells themselves (from the patients).
To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting.
Pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells have the potential to produce various types of tissues/organs.
Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells.
Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells.
Certain types of T cells play the role of commander of immune cells, while other types serve as strong warriors.
Therefore, if we can produce different types of T cells - such as killer T cells, helper T cells, or regulatory T cells - covering a wide range of target antigens, we can provide therapeutic T cells targeting any kind of disease related to the immune system (e.g. cancer, infectious diseases, autoimmune diseases, allergies, etc.).
Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.
Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.
Rebirthel took over all projects and intellectual properties related to killer T cells.
･Regcell raised 620,000,000 JPY through a third-party allocation of new shares.
･Regcell raised 20,000,000 JPY through a third-party allocation of new shares.
OP9 cell line and its genetically modified derivatives
Rebirthel has succeeded all rights of the OP9 cells from Dr. Hiroaki Kodama (who originally established the OP9 cell line).
You are required to obtain a license from Rebirthel for commercial use of the OP9 cell line or its derivatives.
Public Interest Incorporated Foundation KYOTO Industrial Support Organization 21 has announced the names of companies receiving the subsidy for FY 2022. As was the case last year, Rebirthel was select...
HVC Kyoto, Japan’s largest English-spoken pitch event specializing in health care, was held on July 5th, 2022. This event was supported by Japan External Trade Organization (JETRO), Kyoto prefecture, ...
Rebirthel participated in the exhibition “2022 BIO International Convention”, held at San Diego Convention Center, San Diego, the US, from June 13th to June 16th, 2022. Our booth was allocated in the ...
“2022 BIO International Convention (BIO2022)” will be held at San Diego Convention Center from June 13th to June 16th, 2022 and Rebirthel will run a booth in the area of Japan pavilion which Japan Ext...
Informa Pharma Intelligence is the Japanese version of Scrips Awards which is world famous with a history of over 17 years in England. This year, Informa Pharma Intelligence will be held for the first...
Graduate School of Medicine, Kyoto University has its research center on the campus of University of California, San Diego. To encourage the operationalization of research seeds and technologies devel...
Rebirthel Co., Ltd. announces that it entered into an exclusive commercial licensing agreement with Otsuka Pharmaceutical Co., Ltd. for our technologies on CAR-T/TCR-T genetically engineered cell prod...
In the morning edition of Nihon Keizai Shimbun on October 22nd, 2021 (Page 18, Technology), Rebirthel’s research and development activity was introduced. In the article entitled “iPS cell technology r...
Rebirthel participated in the exhibition “Japan Healthcare Venture Summit 2021 (JHVS2021)”, held at PACIFICO Yokohama from October 13th to October 15th, 2021. Our booth was allocated in JST (Japan Sci...
“The dictionary of Biotech Startups in Japan 2021-2022” which covers over 400 bio venture companies was published in June 2021. The news site “Nikkei Biotechnology & Business” is posting a serial ...
We will not use your personal information for any purpose other than contacting customers.